Selection of the initial design for the two-stage continual reassessment method

Xiaoyu Jia, Anastasia Ivanova, Shing M. Lee

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

In the two-stage continual reassessment method (CRM), model-based dose escalation is preceded by a pre-specified escalating sequence starting from the lowest dose level. This is appealing to clinicians because it allows a sufficient number of patients to be assigned to each of the lower dose levels before escalating to higher dose levels. While a theoretical framework to build the two-stage CRM has been proposed, the selection of the initial dose-escalating sequence, generally referred to as the initial design, remains arbitrary, either by specifying cohorts of three patients or by trial and error through extensive simulations. Motivated by a currently ongoing oncology dose-finding study for which clinicians explicitly stated their desire to assign at least one patient to each of the lower dose levels, we proposed a systematic approach for selecting the initial design for the two-stage CRM. The initial design obtained using the proposed algorithm yields better operating characteristics compared to using a cohort of three initial design with a calibrated CRM. The proposed algorithm simplifies the selection of initial design for the two-stage CRM. Moreover, initial designs to be used as reference for planning a two-stage CRM are provided.

Original languageEnglish
Pages (from-to)495-506
Number of pages12
JournalJournal of Biopharmaceutical Statistics
Volume27
Issue number3
DOIs
StatePublished - 4 May 2017

Keywords

  • Adaptive design
  • CRM
  • dose finding
  • indifference intervals
  • initial design
  • phase I study
  • start-up rule

Fingerprint

Dive into the research topics of 'Selection of the initial design for the two-stage continual reassessment method'. Together they form a unique fingerprint.

Cite this